Encapsulating your ideas


SyVento BioTech is a biotechnology company offering comprehensive services in the development of lipid-based nanocarriers and LNP technology. We specialize in the development of lipid-based formulations for pharmaceutical products, including RNA-based drug products.

Our platform solutions enable the efficient design and implementation of projects to encapsulate and deliver therapeutic molecules, such as small molecules, RNA, DNA, and proteins.


Genetic platform

SyVento BioTech’s R&D Team offers technical and scientific support throughout the entire process, including advice on troubleshooting and optimization of RNA synthesis conditions. Our RNA synthesis proficiency guarantees successful results in downstream applications.

By incorporating these important features, our genetic platform for RNA synthesis
provides:

  • high-quality
  • reliablility
  • cost-effectivness

Delivery platform

Our Team’s qualifications and experience provide a wealth of expertise in the development of lipid-based delivery systems.

SyVento BioTech’s LNP delivery systems:

  • help overcome the challenges of delivering fragile and easily degraded RNA molecules
  • improve the efficacy of mRNA based drugs
  • are designed and optimized to achieve specific drug delivery goals
  • their modularity allows for precise control over the size, surface charge, and composition

Manufacturing platform

Our capabilities offer the possibility of scaling the production of formulations based on lipid nanocarriers by transferring solutions developed in the laboratory on a semi-technical and technical scale.

Thanks to the extensive equipment base, we are able to perform:

  • up-scaling starting from very small batches (from lab scale to pilot & demo scale) and up to 50L batches
  • vials filling: 2000-3000 vials per hour (FnF) of continuous filling

Drug development expertise

Our analytical services have been tailored to assist our Partners in their development projects, while also being available to support any standalone analytical initiative.

100% of SyVento BioTech Research and Development Team have PhD in  Life science – mainly biotechnology and chemistry.

Aktualizacja Siedziby SyVento Sp. z o.o. / Change of Registered Office of SyVento sp. z o.o.

June 6, 2023

Aktualizacja Siedziby SyVento Sp. z o.o. / Change of Registered Office of SyVento sp. z o.o.

Jest nam niezmiernie miło poinformować, że SyVento Sp. z o.o. z dniem 5 czerwca 2023 roku oficjalnie przenosi swoją siedzibę. Nowy adres wpisany do Krajowego Rejestru Sądowego przez Sąd Rejestrowy to: ul. Za Górą 19, 32 – 050 Skawina. Ta zmiana jest bezpośrednim wynikiem naszej inwestycji w Centrum Badań i Rozwoju Biotechnologicznego w Skawinie oraz […]

SyVento BioTech Attends BIO International Convention 2023

June 6, 2023

SyVento BioTech Attends BIO International Convention 2023

SyVento BioTech Attends BIO International Convention 2023 SyVento BioTech is currently participating in the BIO International Convention 2023. The organization’s representatives at this event are Business Development Manager Dr. Oskar Szelest, R&D Director Dominik Lipka, PhD Eng., and Chairman of the Supervisory Board, Tomasz Piec. This convention is hosting over 15,000 biotechnology and pharmaceutical leaders […]

RNA Leaders Europe Congress – Meet us at stand 16

March 13, 2023

RNA Leaders Europe Congress – Meet us at stand 16

Tomasz Piec, President of Supervisory Board, Dominik Lipka, PhD Eng., Director of Research and Development, Board Member, and Oskar Szelest, PhD, Business Development Manager, will be attending this year’s RNA Leaders conference.

SyVento and OncoArendi agreement

December 9, 2021

SyVento and OncoArendi agreement

SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02. Details in following press release.

Thank you for exciting time during 9th International mRNA Health Conference

November 16, 2021

Thank you for exciting time during 9th International mRNA Health Conference

During the past days, we looked at the exciting field of mRNA from different perspectives & gotten insights into the current research. It was a pleasure being with you.

Join & Meet us at 9th Annual International mRNA Health Conference

October 30, 2021

Join & Meet us at 9th Annual International mRNA Health Conference

We are looking forward to exploring the rapidly advancing mRNA technology together with other conference participants during 9th Annual International mRNA Health Conference.

Contact Us


Let's collaborate and create quality liposome encapsulated drugs together.